The energy around Recursion Pharmaceuticals is different this week. If you’ve been watching the rxrx stock price today, you’ve probably noticed it’s finally showing some teeth, trading around $4.85 with a decent bit of momentum. It’s up over 3% in just one session. Honestly, for a company that’s spent a lot of time being the "poster child" for AI drug discovery without much to show for it in the clinic, this recent movement feels like a shift in the narrative.
People are starting to look past the "cool tech" and looking at the actual drugs.
Yesterday, Jan 13, 2026, the company’s CEO, Najat Khan, took the stage at the J.P. Morgan Healthcare Conference. That's usually a high-stakes moment where biotechs either crash or fly. Recursion didn't crash. Instead, they doubled down on the idea that they aren't just a software company—they’re a "TechBio" powerhouse that’s starting to deliver on its pipeline. The rxrx stock price today reflects a market that is slowly, cautiously, becoming a believer again.
The TUPELO Factor: Why the Market is Waking Up
You can’t talk about the stock right now without mentioning REC-4881. It’s their lead candidate for Familial Adenomatous Polyposis (FAP), a nasty rare condition that leads to colon cancer. Recent data from the Phase 1b/2 TUPELO trial was, frankly, better than most expected. We’re talking about a 43% median reduction in polyp burden after just 12 weeks.
That’s huge.
Most biotechs in this space struggle to show that kind of "rapid and durable" response. What really caught the eye of the big institutional players, though, was the fact that 82% of patients kept those reductions even after they stopped taking the drug for three months. That’s the kind of staying power that makes analysts at firms like JPMorgan change their tune. In fact, JPMorgan recently upgraded the stock to "Overweight" with a price target of $11.00.
When a major bank says a stock could more than double, people pay attention.
The rxrx stock price today is essentially a bet on whether that $11 target is a pipe dream or a logical destination. Right now, the stock is fighting its way out of a long-term slump. It’s still way off its 52-week high of **$12.36**, but it’s clear of the $3.79 floor it hit earlier. It feels like the "show me" phase of the investment cycle is finally starting to pay off.
Deep Pockets and AI Muscle
One thing that makes Recursion stand out from the sea of failing biotechs is its list of friends. They’ve got partnerships with Roche, Genentech, and Sanofi that could eventually lead to billions in milestones. They already cleared over $500 million in cumulative payments.
Then there’s the NVIDIA connection.
Recursion is basically using NVIDIA’s H100s to run "BioHive-2," which they claim is the most powerful supercomputer in the biopharma world. It’s not just for show. They’re using it to map out human biology in a way that’s almost impossible for humans to do manually. The goal? Stop the 90% failure rate that haunts the drug industry.
While the rxrx stock price today is hovering under five bucks, the company is sitting on a massive cash pile of about $755 million. They’ve got enough runway to keep the lights on and the lab robots running until the end of 2027. That’s a luxury most small-cap biotechs don't have right now.
The Elephant in the Room: Insider Selling
If everything is so great, why are the bosses selling? That’s the question everyone asks when they see the SEC filings. This month, we saw Director Blake Borgeson sell nearly a million dollars worth of shares, and Co-Founder Chris Gibson sold another $170k.
Kinda looks bad, right?
Well, if you dig into the paperwork, these were 10b5-1 trading plans. Basically, these sales were scheduled months or even a year ago. It’s a way for executives to get some liquidity without getting sued for insider trading. Still, it’s a bit of a psychological drag on the rxrx stock price today. Investors don't like seeing the "smart money" head for the exit, even if it's just for a new house or a tax bill.
✨ Don't miss: Crypto All Stars Price Prediction: What Most People Get Wrong
Analyzing the RXRX Price Targets
Wall Street is a bit of a house divided on this one. You’ve got a "Hold" consensus overall, but the range is wild.
- The Bulls ($11 - $11.50): These guys, including JPMorgan, think the FAP drug is a blockbuster in waiting and that the AI platform will churn out three more winners by 2027.
- The Skeptics ($3.00 - $4.00): This crowd thinks the cash burn is too high. They’re worried that by the time a drug actually hits the market, the company will have diluted the stock to death to stay alive.
- The Middle Ground ($7.00): This is the average target. It assumes the company successfully transitions its Phase 2 trials into Phase 3 without any major explosions.
If you’re looking at the rxrx stock price today, you’re seeing the tug-of-war between these groups in real-time. The volume is high—over 16 million shares traded today—which shows there's a lot of conviction on both sides.
What to Do Next
If you're holding RXRX or thinking about jumping in, the game has changed from "AI hype" to "clinical execution." The next 12 to 18 months are everything.
Keep a close eye on the TUPELO trial updates. If they can move into a pivotal Phase 3 for FAP, that's the catalyst that could push this back toward double digits. Also, watch the Roche/Genentech updates. Any new "map" or program initiation usually comes with a fat check that extends their cash runway without hurting current shareholders.
Monitor the rxrx stock price today for a sustained break above the $5.00 psychological resistance. If it can hold that level for a few days, it might suggest the bottom is officially in.
Finally, check the "BioHive" updates. If Recursion can prove that their AI actually speeds up the IND-enabling process (getting a drug ready for human trials) better than traditional methods, the valuation will stop being compared to biotechs and start being compared to high-growth tech firms.
Actionable Insights:
- Check the $5.00 level: A daily close above $5.00 on high volume is a classic bullish signal for this stock.
- Watch the JPM fallout: Updates from the J.P. Morgan conference usually trickle out for a week. Watch for any secondary analyst notes or price target hikes.
- Hedge your bets: Biotech is notoriously volatile. If you're long, make sure your position size reflects the risk of a trial failure, which is always a non-zero possibility in this industry.